losartan and tempol

losartan has been researched along with tempol in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Chen, J; Chen, Z; Cheng, Z; Hu, G; Jiang, D; Li, Q; Lu, M; Peng, Z; Tao, L; Xiong, X	1

Other Studies

2 other study(ies) available for losartan and tempol

Article	Year
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy. Bioorganic & medicinal chemistry letters, 2018, 01-15, Volume: 28, Issue:2 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Discovery; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Mice; Molecular Structure; NIH 3T3 Cells; Oxidative Stress; Piperazines; Pyridones; Rats; Structure-Activity Relationship	2018

Article

Year

Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.

Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012

Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.

Bioorganic & medicinal chemistry letters, 2018, 01-15, Volume: 28, Issue:2

Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Discovery; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Mice; Molecular Structure; NIH 3T3 Cells; Oxidative Stress; Piperazines; Pyridones; Rats; Structure-Activity Relationship

2018